利妥昔单抗 + mVPDL 治疗 CD20(+) 成人急性淋巴细胞白血病 (RADICAL)
评估利妥昔单抗加改良 VPDL 治疗新诊断 CD20 阳性成人急性淋巴细胞白血病疗效的 2 期研究
研究概览
详细说明
根据“韩国血液学会成人 ALL 工作组”对成人 ALL 进行的基于柔红霉素的升级方案的最新结果(数据在 2010 年伊利诺伊州芝加哥 ASCO 年会上公布), 90.6% 的 CR 率令人满意,但 2 年/3 年无病生存率 (DFS) 令人失望(分别为 43.6% 和 39.9%),这意味着充分的缓解后治疗以控制微小残留病达到CR后对改善成人ALL的转归非常重要。
同种异体造血细胞移植 (AlloHCT) 被推荐作为成人 ALL 患者的缓解后治疗,并且已尝试降低强度调节以降低 TRM 率。 然而,由于缺乏 HLA 匹配供体、年龄限制和合并合并症,许多患者接受了巩固化疗而不是 alloHCT(在我们之前提到的研究中纳入的 190 名患者中,只有 52.3% 接受了 alloHCT)。
最近,成人 ALL 的治疗似乎停滞不前,这可能是由于进一步加强化疗剂量的临界点。 就增加的发病率和死亡率而言,剂量递增策略在成人 ALL 的治疗中有很多困难,更不用说这些策略的疗效了。 因此,迫切需要新的、最好是非化疗的方法(可能是靶向治疗)。
对于 Ph(+) ALL,BCR/ABL 酪氨酸激酶抑制剂的引入改善了治疗结果,且毒性可耐受。 对 Ph(-) ALL 应用类似的策略,用单克隆抗体靶向白血病表面抗原是另一种有前途的策略。
已知在 22-48% 的前 B ALL 中发现至少 20% 的 CD 20 表达,并且似乎与不良预后相关,尽管在儿科患者中存在争议。 基于 B 细胞 NHL 结果的显着改善,关于使用利妥昔单抗一线治疗 CD20 阳性前体 B 细胞 ALL 的初步数据表明它的使用可能是有益的。 特别是,单克隆抗体被认为与化疗联合使用并在微小残留病灶状态下治疗时更有效,这表明评估利妥昔单抗联合当前成人 ALL 化疗的兴趣。 关于利妥昔单抗联合化疗疗效的最新数据表明,在较年轻(年龄 < 60 岁)中,与标准 hyper-CVAD 相比,改良 hyperCVAD 和利妥昔单抗方案的 CR 率和 OS 率优于标准 hyper-CVAD(70% 对 38%,p<0.001) ) CD20 阳性子集,尽管它是对接受不同方案 5 治疗的不同患者组的分析。
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Busan、大韩民国
- Inje University Busan Paik Hospital
-
Busan、大韩民国
- Dong-A University College of Medicine
-
Busan、大韩民国
- Division of Hematology-Oncology, Dong-A University College of Medicine
-
Busan、大韩民国
- Inje University Haeundae-Paik Hospital
-
Busan、大韩民国
- Kosin University College of Medicine, Kosin University Gospel Hospital
-
Daegu、大韩民国
- Keimyung University Dongsan Medical Center
-
Daegu、大韩民国
- Catholic University of Daegu School of Medicine
-
Daegu、大韩民国
- Yeungnam University College of Medicine
-
Daegu、大韩民国
- Kyungpook National Unviersity Hospital
-
Daejeon、大韩民国
- Chungnam National University Hospital
-
Seoul、大韩民国
- Seoul National University Hospital
-
Seoul、大韩民国
- Ewha Womans University Mokdong Hospital
-
Seoul、大韩民国
- Chung-Ang University Hospital
-
Seoul、大韩民国
- Korea University Anam Hospital
-
Seoul、大韩民国
- Soonchunhyang University Hospital
-
Seoul、大韩民国
- Asan Medical Center, University of Ulsan College of Medicine
-
Ulsan、大韩民国
- Ulsan University Hospital, University of Ulsan College of Medicine
-
-
Chollanamdo
-
Hwasun、Chollanamdo、大韩民国
- Chonnam National University Hwasun Hospital
-
-
Kongki
-
Ilsan、Kongki、大韩民国
- Hematologic Oncology Clinic, National Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
- 既往未接受治疗且患有 ALL 或高危淋巴母细胞淋巴瘤的患者。
- 白血病原始细胞在诊断时表达 ≥ 20% CD20 抗原的患者
- 没有先前的白血病化疗(允许使用羟基脲或白细胞去除术。)
- 预计寿命3个月以上
- ECOG 性能状态为 2 或更低,Karnofsky 量表 > 60
- 超声心动图或心脏扫描(MUGA 扫描)显示心功能良好 (EF>45%)
- 15 岁及以上。
- 足够的肾功能(肌酐<1.5 mg/dL)
- 足够的肝功能。 (胆红素<1.5 mg/dL,转氨酶水平<正常上限的3倍[肝转移或肝肿大患者为5倍])。 即使初始水平超过上限,当第 8 天的水平满足纳入标准时,患者也可以接受。
- 根据每个机构人类研究委员会的指导方针,所有患者都签署了书面知情同意书。
排除标准:
- 急性双表型白血病、急性双克隆白血病或急性混合性白血病
- 存在严重的不受控制的活动性感染
- 存在不受控制的出血
- 任何并存的重大疾病或器官衰竭
- 患有精神障碍或精神缺陷的患者严重到无法依从治疗,并且不可能获得知情同意
- 不想采取充分避孕措施的哺乳期妇女、孕妇、育龄期妇女
- 先前诊断为恶性肿瘤的患者,除非在以治愈为目的的治疗后至少 5 年无病(除了治愈性治疗的非黑色素瘤皮肤癌、原位癌或宫颈上皮内瘤变)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:北美
- 介入模型:单组
- 屏蔽:没有任何
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:利妥昔单抗+mVPDL
CD20(+)、新诊断成人 ALL 并接受利妥昔单抗 + mVPDL 治疗方案的患者
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
无复发生存 (RFS) 率
大体时间:2年
|
2年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
完全缓解 (CR) 率
大体时间:4周(从诱导治疗开始)
|
在总患者/子集 A 的每个子集中。 [子集A]
|
4周(从诱导治疗开始)
|
|
无复发生存率
大体时间:2年
|
在 A 和 B 的每个子集中的患者中。 [子集A]
|
2年
|
|
总生存率
大体时间:2年
|
在总患者/A 和 B 的每个子集中 [子集A]
|
2年
|
|
急性/慢性移植物抗宿主病的累积发病率和最大严重程度
大体时间:2年
|
在alloHCT接受者中
|
2年
|
合作者和调查者
调查人员
- 首席研究员:Young Don Joo, MD, PhD、Inje University
出版物和有用的链接
一般刊物
- Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
- Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, Scime R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007 Aug;40(3):273-7. doi: 10.1038/sj.bmt.1705725. Epub 2007 Jun 4.
- Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 Dec 1;106(12):3725-32. doi: 10.1182/blood-2005-01-0016. Epub 2005 Aug 25.
- Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 Feb 15;111(4):1827-33. doi: 10.1182/blood-2007-10-116582. Epub 2007 Nov 29.
- Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fiere D, Leverger G, Dombret H, Baruchel A. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003 Mar 1;21(5):774-80. doi: 10.1200/JCO.2003.02.053. Epub 2003 Mar 1.
- Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18;113(25):6330-7. doi: 10.1182/blood-2008-04-151860. Epub 2008 Aug 14.
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. doi: 10.1200/JCO.2005.09.131. Epub 2005 May 2.
- Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, Rubnitz JE, Hijiya N, Howard SC, Cheng C, Pui CH. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006 Nov 15;108(10):3302-4. doi: 10.1182/blood-2006-04-016709. Epub 2006 Aug 8.
- Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Mar 26;113(13):2902-5. doi: 10.1182/blood-2008-10-184093. Epub 2009 Jan 28.
- Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, Katoh N, Kishimoto S, Shimazaki C. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006 Jan;20(1):172-3. doi: 10.1038/sj.leu.2403996. No abstract available.
- Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15;108(2):756-62. doi: 10.1182/blood-2006-01-0233. Epub 2006 Mar 21.
- Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M; Swedish Adult Acute Lymphocytic Leukemia Group; Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006 Oct 1;107(7):1551-61. doi: 10.1002/cncr.22189.
- Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, April F, Perona G. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998 Feb;12(2):144-9. doi: 10.1038/sj.leu.2400912.
- Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010 Oct 1;116(19):4580-9. doi: 10.1002/cncr.25319.
- Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Aug 1;27(22):3634-41. doi: 10.1200/JCO.2008.20.2960. Epub 2009 Jul 6.
- Pituch-Noworolska A, Hajto B, Mazur B, Sonta-Jakimczyk D, Balwierz W, Janota-Krawczyk E, Kowalska H, Malinowska I, Modzelewska M, Wasik M. Expression of CD20 on acute lymphoblastic leukemia cells in children. Neoplasma. 2001;48(3):182-7.
- Maury S, Huguet F, Leguay T, Lacombe F, Maynadie M, Girard S, de Labarthe A, Kuhlein E, Raffoux E, Thomas X, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Rousselot P, Macintyre E, Ifrah N, Dombret H, Bene MC; Group for Research on Adult Acute Lymphoblastic Leukemia. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010 Feb;95(2):324-8. doi: 10.3324/haematol.2009.010306. Epub 2009 Sep 22.
- Borowitz MJ, Shuster J, Carroll AJ, Nash M, Look AT, Camitta B, Mahoney D, Lauer SJ, Pullen DJ. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood. 1997 Jun 1;89(11):3960-6.
- Al Gwaiz LA, Bassioni W. Immunophenotyping of acute lymphoblastic leukemia using immunohistochemistry in bone marrow biopsy specimens. Histol Histopathol. 2008 Oct;23(10):1223-8. doi: 10.14670/HH-23.1223.
- Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G, von Stackelberg A. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica. 2006 Feb;91(2):272-3.
- Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80. doi: 10.1002/cncr.21776.
- Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20;28(24):3880-9. doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26.
- Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG; Children's Oncology Group. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Feb;52(2):177-81. doi: 10.1002/pbc.21753.
- Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat Rev. 2009 Dec;35(8):653-61. doi: 10.1016/j.ctrv.2009.07.004. Epub 2009 Aug 13.
- Dworzak MN, Schumich A, Printz D, Potschger U, Husak Z, Attarbaschi A, Basso G, Gaipa G, Ratei R, Mann G, Gadner H. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008 Nov 15;112(10):3982-8. doi: 10.1182/blood-2008-06-164129. Epub 2008 Sep 9.
- Stanciu-Herrera C, Morgan C, Herrera L. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. Leuk Res. 2008 Apr;32(4):625-32. doi: 10.1016/j.leukres.2007.07.002. Epub 2007 Aug 15.
- Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B, Ratei R, Coliva T, Valsecchi MG, Biondi A, Dworzak MN; I-BFM-ALL-FCM-MRD Study Group. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005 Jan;19(1):49-56. doi: 10.1038/sj.leu.2403559.
- Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol. 2004 Apr;83(4):201-5. doi: 10.1007/s00277-003-0752-8. Epub 2003 Nov 26.
- Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011 May 12;117(19):5261-3. doi: 10.1182/blood-2011-01-329573. Epub 2011 Mar 14.
- Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant. 2008 May;41(10):909-11. doi: 10.1038/bmt.2008.12. Epub 2008 Feb 18. No abstract available.
- Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006 Aug;38(3):203-9. doi: 10.1038/sj.bmt.1705425. Epub 2006 Jun 26.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.